Press Releases
Cosma SA and SOMAÍ Pharmaceuticals partner to revolutionize Poland with the most innovative cannabis-based solutions
Cosma SA, a leader in cannabis-based pharmaceutical advancements, and SOMAÍ Pharmaceuticals, a fully vertically integrated Multinational Operator (MCO) in the global medical cannabis markets, are pleased to announce a strategic partnership that appoints Cosma as the Marketing Authorisation Holder (MAH) for Cosma and SOMAÍ’s next-generation cannabis-based products. This collaboration underscores our joint commitment to pioneering a broad and innovative portfolio and significantly expands our product offering and market presence.
Our partnership is dedicated to driving innovation in the pharmaceutical industry. Together, Cosma SA and SOMAÍ Pharmaceuticals will present a range of advanced cannabis-based product lines, including several purified oral solution formulations and inhalation extracts, for Polish patients. Oral Solutions formula based on purified full-spectrum cannabis extract that combines a wide variety of THC/CBD ratios, genetics and formulations with different terpene and flavonoid options to cover a wide range of medical conditions, while improving patient experience and adherence. Oral solutions and inhalation extracts are available in three specialized lines: Essentials, Origins and Senses.
These unique strain products continue to undergo rigorous Polish registration processes, ensuring that they meet the highest standards of quality and efficacy. In addition to SOMAÍ’s Cosma extract, which is expected to be registered and available on the market later this year, 2024, we expect the newest products to be registered and available on the market from the end of 2025.
In our strengthened partnership, Cosma SA will act as the MAH, leveraging its expertise to navigate the complex regulatory landscape and ensure timely market access for these products. SOMAÍ Pharmaceuticals will act as the Active Pharmaceutical Ingredient (API) Manufacturer, bringing its advanced knowledge and cutting-edge manufacturing practices to the table.
Przemysław Lahuta, Chairman of Cosma SA, said: “We anticipate a significant increase in the registration of 45 new products over the next few years as we pursue our goal of becoming the CEE Cannabis Leader. Our collaboration demonstrates our commitment to providing advanced, high-quality healthcare solutions for Polish patients and the medical industry. In line with our strategic goals, we continue to develop the Cosma brand and expand the distribution of SOMAÍ’s new products.”
Michael Sassano, Founder and Interim CEO of SOMAÍ Pharmaceuticals, says: “Through our partnership with Cosma, we are committed to improving Polish patients’ access to innovative, best-performing and highest-quality tasting solutions that have the potential to change their lives for the better.
About Cosma SA
Cosma SA is a leading pharmaceutical company headquartered in Warsaw, Poland, known for its commitment to innovation, quality and excellence in the healthcare industry. Focused on the development and distribution of a wide range of medical products, Cosma continues to drive advancements that improve patient outcomes and enhance the overall healthcare landscape.
Information about SOMAÍ Farmacêutica
SOMAÍ Pharmaceuticals is a leading European company with vertically integrated EU-GMP Multi-Country Operations (MCO), with a global distribution presence of the largest and most advanced portfolio of EU GMP certified pharmaceutical extracts containing cannabinoids.
SOMAÍ has state-of-the-art indoor cultivation and production facilities in Lisbon, Portugal, and has global sales teams in the largest medical cannabis markets. SOMAÍ continues to make global brand acquisitions and partnerships that make the company one of the few and first vertically integrated European companies in the EU, able to meet the diverse needs of the rapidly growing global cannabis markets.
____________________________________________________________________________________________________
[Disclaimer: Please note that this text was originally written in Portuguese and is translated into English and other languages using an automatic translator. Some words may differ from the original and typos or errors may occur in other languages.]____________________________________________________________________________________________________
What do you do with €3 a month? Become one of our Patrons! If you believe that independent cannabis journalism is necessary, subscribe to one of the levels of our Patreon account and you will have access to unique gifts and exclusive content. If there are many of us, we can make a difference with little!
CannaReporter
Diego Quattrone: "If we consider all cannabis users, it's clear that we're talking about a very small percentage of people who develop psychotic disorders."
Diego Quattrone is a psychiatrist, researcher and Professor of Mental Health and Psychological Sciences at King's College London, United Kingdom.
GNR Faro | Vilamoura – Seizure of more than 700 products in a cannabis store
The Faro Territorial Command, through the Loulé Territorial Detachment, carried out an operation on July 8th...
Systematic review and meta-analysis demonstrate the potential of CBD in reducing seizure frequency in Epilepsy
Epilepsy, as a chronic neurological disease, affects a substantial number of individuals globally, with a significant subset...
Portugal: New cannabis seizure in Grândola exposes yet another illegal trafficking operation disguised as a medicinal facility
As part of the operation to combat drug trafficking, the Judicial Police (PJ) seized more than 2.200 kilos today...
North Macedonia: Government to review company licenses after seizing cannabis destined for the illicit market
“All licenses granted to companies processing cannabis for medicinal purposes will be reviewed.” The government of North Macedonia...
Portugal: New Operation “Ortiga” seizes 2 tons of cannabis and arrests two foreign citizens
The investigation that the Judiciary Police began in May and which targets medicinal cannabis companies in Portugal had today...
Thailand: New cannabis regulations aren't as bad as they seem. Here's what's really at stake in the country
The Thai government recently announced its intention to review its cannabis legislation, with the aim of limiting...
Lorraine Nolan chosen to head European Drugs Agency (EUDA)
The Executive Assembly of the European Drugs Agency (EUDA) has appointed Irishwoman Lorraine Nolan to take up the position of Director...
Cannabis Europa: “Doctors continue to leave medical school without having learned about the endocannabinoid system”
The phrase is from Niall Ivers, co-founder of Cantourage, and reveals a systemic problem in the medicinal cannabis sector in...
Hungary: New drug policy includes zero tolerance and hate campaigns
The Hungarian government, in power for 15 years, has consistently used marginalized groups as scapegoats for its problems,...
